The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Naratuximab emtansine and rituximab in DLBCL
Despite the advent of various therapies such as polatuzumab vedotin with rituximab and bendamustine, tafasitamab with lenalidomide, and selinexor, relapsed/refractory diffuse large B-cell lymphoma (DLBCL) remains an unmet need, and novel theapies are required. Moshe Y. Levy, MD, Baylor University Medical Center, Dallas, TX, discusses results from the Phase II trial (NCT02564744) of naratuximab emtansine, an anti-CD37 antibody-drug conjugate (ADC), in patients with relapsed/refractory DLBCL and other forms of non-Hodgkin B-cell lymphomas. Patients received naratuximab emtansine with rituximab, and a complete response was reported in a third of patients. The regimen additionally had a tolerable safety profile, as demonstrated by the quality of life questionnaires. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Disclosures
Dr Levy reports consultant/speaker fees from: Abbvie, Amgen, BMS, Janssen, Karyopharm, Morphosys, Seattle genetics, Takeda, Astra Zeneca, Beigene, Gilead, Jazz, TG therapeutics, Dova, Epizyme, GSK, and Novartis.
